{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:31:18Z","timestamp":1791613878137,"version":"4.3.4"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.critrevonc.2024.104591","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T07:40:05Z","timestamp":1733816405000},"page":"104591","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Recent advances in the study of immune checkpoint inhibitor-associated pneumonia"],"prefix":"10.1016","volume":"206","author":[{"given":"Xiaoan","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5767-5127","authenticated-orcid":false,"given":"Chunyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2024.104591_bib1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/978-3-030-79308-1_14","article-title":"Pulmonary Toxicities of Immunotherapy","volume":"1342","author":"Altan","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104591_bib2","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.chest.2021.02.032","article-title":"Immune checkpoint inhibitor-related pneumonitis in lung cancer: real-world incidence, risk factors, and management practices across six health care centers in north carolina","volume":"160","author":"Atchley","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.critrevonc.2024.104591_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1296890","article-title":"Interstitial lung disease: a review of classification, etiology, epidemiology, clinical diagnosis, pharmacological and non-pharmacological treatment","volume":"11","author":"Althobiani","year":"2024","journal-title":"Front. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104591_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102030","article-title":"Antiplatelet drugs may increase the risk for checkpoint inhibitor-related pneumonitis in advanced cancer patients","volume":"8","author":"Araki","year":"2023","journal-title":"ESMO Open"},{"issue":"17","key":"10.1016\/j.critrevonc.2024.104591_bib5","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"New Engl. J. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104591_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics14060613","article-title":"Pulmonary adverse events in cancer immunotherapy: case studies of CT patterns","volume":"14","author":"Bocchini","year":"2024","journal-title":"Diagnostics"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104591_bib7","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104591_bib8","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1053\/crad.2001.0792","article-title":"Drug-induced lung disease: high-resolution CT and histological findings","volume":"57","author":"Cleverley","year":"2002","journal-title":"Clin. Radio."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104591_bib9","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1183\/09031936.06.00013505","article-title":"Cryptogenic organising pneumonia","volume":"28","author":"Cordier","year":"2006","journal-title":"Eur. Respir. J."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104591_bib10","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1164\/rccm.201501-0017OC","article-title":"Early chest computed tomography scan to assist diagnosis and guide treatment decision for suspected community-acquired pneumonia","volume":"192","author":"Claessens","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104591_bib11","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1513\/AnnalsATS.201609-728PS","article-title":"Acute respiratory distress syndrome and diffuse alveolar damage. New insights on a complex relationship","volume":"14","author":"Cardinal-Fern\u00e1ndez","year":"2017","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.critrevonc.2024.104591_bib12","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2147\/CMAR.S136818","article-title":"Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis","volume":"9","author":"Chuzi","year":"2017","journal-title":"Cancer Manag Res."},{"key":"10.1016\/j.critrevonc.2024.104591_bib13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2020.08.015","article-title":"Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors","volume":"150","author":"Chu","year":"2020","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104591_bib14","doi-asserted-by":"crossref","first-page":"295","DOI":"10.21037\/tlcr-22-72","article-title":"Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer","volume":"11","author":"Chao","year":"2022","journal-title":"Transl. Lung Cancer Res."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104591_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005323","article-title":"Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis","volume":"10","author":"Franken","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2024.104591_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1302233","article-title":"The impact of pulmonary artery to ascending aorta diameter ratio progression on the prognosis of NSCLC patients treated with immune checkpoint inhibitors","volume":"15","author":"Gong","year":"2024","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104591_bib17","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1186\/s12885-021-08353-y","article-title":"Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis","volume":"21","author":"Huang","year":"2021","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104591_bib18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/1759-7714.13736","article-title":"Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors","volume":"12","author":"Isono","year":"2021","journal-title":"Thorac. Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104591_bib19","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/oncolo\/oyac118","article-title":"Atezolizumab for pretreated non-small cell lung cancer with idiopathic interstitial pneumonia: final analysis of phase II AMBITIOUS study","volume":"27","author":"Ikeda","year":"2022","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104591_bib20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13613-020-00761-w","article-title":"Immune-related adverse events: a retrospective look into the future of oncology in the intensive care unit","volume":"10","author":"Joseph","year":"2020","journal-title":"Ann. Intensive Care"},{"key":"10.1016\/j.critrevonc.2024.104591_bib21","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/531302","article-title":"Diffuse alveolar damage: a common phenomenon in progressive interstitial lung disorders","volume":"2011","author":"Kaarteenaho","year":"2011","journal-title":"Pulm. Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104591_bib22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s13054-015-0949-y","article-title":"Diffuse alveolar damage associated mortality in selected acute respiratory distress syndrome patients with open lung biopsy","volume":"19","author":"Kao","year":"2015","journal-title":"Crit. Care"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104591_bib23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41416-018-0155-1","article-title":"Immune dysregulation in cancer patients developing immune-related adverse events","volume":"120","author":"Khan","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104591_bib24","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.21037\/jtd-22-93","article-title":"Immune checkpoint inhibitor-related interstitial lung disease in patients with advanced non-small cell lung cancer: systematic review of characteristics, incidence, risk factors, and management","volume":"14","author":"Kim","year":"2022","journal-title":"J. Thorac. Dis."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104591_bib25","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S1470-2045(21)00241-2","article-title":"Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111\/KEYNOTE-146): a phase 1b\/2 study","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104591_bib26","article-title":"Distinct immunophenotypes of T cells in bronchoalveolar lavage fluid from leukemia patients with immune checkpoint inhibitors-related pulmonary complications","volume":"11","author":"Kim","year":"2020","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104591_bib27","doi-asserted-by":"crossref","first-page":"916","DOI":"10.2214\/AJR.09.3940","article-title":"Cryptogenic organizing pneumonia: serial high-resolution CT findings in 22 patients. AJR","volume":"195","author":"Lee","year":"2010","journal-title":"Am. J. Roentgenol."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104591_bib28","first-page":"761","article-title":"[Dyspnea with multiple bilateral lung opacities on CT scan]","volume":"47","author":"Li","year":"2024","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104591_bib29","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1111\/1759-7714.13967","article-title":"Severe immune-related hyperthermia followed by immune-related pneumonitis with PD-1 inhibitor (sintilimab) in small cell lung cancer: a case report","volume":"12","author":"Li","year":"2021","journal-title":"Thorac. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104591_bib30","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1158\/1078-0432.CCR-18-2795","article-title":"Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy","volume":"25","author":"Lim","year":"2019","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2024.104591_bib31","article-title":"Peripheral blood biomarkers for early diagnosis, severity, and prognosis of checkpoint inhibitor-related pneumonitis in patients with lung cancer","volume":"11","author":"Lin","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104591_bib32","article-title":"Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: a meta-analysis of randomized controlled trials","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2024.104591_bib33","article-title":"Predictive factors and prognosis of immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer patients","volume":"13","author":"Liu","year":"2023","journal-title":"Front Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104591_bib34","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.ijrobp.2023.01.006","article-title":"Dose-limiting pulmonary toxicity in a phase 1\/2 study of radiation and chemotherapy with ipilimumab followed by nivolumab for patients with stage 3 unresectable non-small cell lung cancer","volume":"116","author":"Liveringhouse","year":"2023","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2024.104591_bib35","first-page":"697","article-title":"Clinical observation on patients with immune checkpoint inhibitor-associated pneumonia treated with lung detoxification soup combined with methylprednisolone","volume":"41","author":"Liu","year":"2024","journal-title":"Tianjin Tradit. Chin. Med."},{"key":"10.1016\/j.critrevonc.2024.104591_bib36","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.3389\/fphar.2018.01430","article-title":"The relative risk and incidence of immune checkpoint inhibitors related pneumonitis in patients with advanced cancer: a meta-analysis","volume":"9","author":"Ma","year":"2018","journal-title":"Front Pharm."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104591_bib37","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s12890-024-03041-6","article-title":"Risk factors of immune checkpoint inhibitor-related pneumonitis after neoadjuvant immunochemotherapy for resectable NSCLC","volume":"24","author":"Mao","year":"2024","journal-title":"BMC Pulm. Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104591_bib38","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/1759-7714.14718","article-title":"Clinical significance of interstitial lung abnormalities and immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer","volume":"14","author":"Murata","year":"2023","journal-title":"Thorac. Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104591_bib39","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104591_bib40","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104591_bib41","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000575","article-title":"Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis","volume":"4","author":"Park","year":"2019","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104591_bib42","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1378\/chest.116.5.1168","article-title":"The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: a prospective study","volume":"116","author":"Raghu","year":"1999","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104591_bib43","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1183\/09031936.00094910","article-title":"Idiopathic nonspecific interstitial pneumonia: an interstitial lung disease associated with autoimmune disorders?","volume":"38","author":"Romagnoli","year":"2011","journal-title":"Eur. Respir. J."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104591_bib44","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1148\/radiol.2442060640","article-title":"Chronic hypersensitivity pneumonitis: CT features comparison with pathologic evidence of fibrosis and survival","volume":"244","author":"Sahin","year":"2007","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104591_bib45","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.medin.2010.08.001","article-title":"Study on the clinicopathological correlation in the secondary acute respiratory distress syndrome","volume":"35","author":"Sarmiento","year":"2011","journal-title":"Med Intensiv."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104591_bib46","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.rmed.2011.04.001","article-title":"Discrepancy between clinical criteria for diagnosing acute respiratory distress syndrome secondary to community acquired pneumonia with autopsy findings of diffuse alveolar damage","volume":"105","author":"Sarmiento","year":"2011","journal-title":"Respir. Med"},{"issue":"36","key":"10.1016\/j.critrevonc.2024.104591_bib47","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104591_bib48","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/1759-7714.14274","article-title":"Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China","volume":"13","author":"Shi","year":"2022","journal-title":"Thorac. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104591_bib49","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00262-019-02431-8","article-title":"Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody","volume":"69","author":"Shibaki","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104591_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/jcm7100356","article-title":"Drug-induced interstitial lung disease: a systematic review","volume":"7","author":"Skeoch","year":"2018","journal-title":"J. Clin. Med"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104591_bib51","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/ajco.13380","article-title":"Programmed cell death 1 (PD-1)\/PD-ligand 1(PD-L1) inhibitors-related pneumonitis in patients with advanced non-small cell lung cancer","volume":"16","author":"Sun","year":"2020","journal-title":"Asia Pac. J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104591_bib52","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1172\/JCI128654","article-title":"The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis","volume":"129","author":"Suresh","year":"2019","journal-title":"J. Clin. Invest"},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104591_bib53","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jtho.2020.04.002","article-title":"Assessment of immune-related interstitial lung disease in patients With NSCLC treated with immune checkpoint inhibitors: a multicenter prospective study","volume":"15","author":"Suzuki","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104591_bib54","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/CJI.0000000000000451","article-title":"Risk factors for refractory immune checkpoint inhibitor-related pneumonitis in patients with lung cancer","volume":"46","author":"Tan","year":"2023","journal-title":"J. Immunother."},{"key":"10.1016\/j.critrevonc.2024.104591_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.109821","article-title":"Cancer immunotherapy: pros, cons and beyond","volume":"124","author":"Tan","year":"2020","journal-title":"Biomed. Pharm."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104591_bib56","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1782","article-title":"Integrated multi-omics profiling landscape of organising pneumonia","volume":"14","author":"Tang","year":"2024","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.critrevonc.2024.104591_bib57","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.lungcan.2021.03.014","article-title":"Non-inferior clinical outcomes of immune checkpoint inhibitors in non-small cell lung cancer patients with interstitial lung disease","volume":"155","author":"Tasaka","year":"2021","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104591_bib58","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med"},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104591_bib59","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1164\/rccm.200611-1685OC","article-title":"Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project","volume":"177","author":"Travis","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104591_bib60","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1774314","article-title":"Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review","volume":"9","author":"Wagner","year":"2020","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104591_bib61","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/cam4.3600","article-title":"Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis: a single-institution retrospective study","volume":"10","author":"Wang","year":"2021","journal-title":"Cancer Med"},{"issue":"41","key":"10.1016\/j.critrevonc.2024.104591_bib62","article-title":"The relationship between pneumonitis and programmed cell death-1\/programmed cell death ligand 1 inhibitors among cancer patients: a systematic review and meta-analysis","volume":"99","author":"Xu","year":"2020","journal-title":"Med. (Baltim. )"},{"key":"10.1016\/j.critrevonc.2024.104591_bib63","first-page":"114","article-title":"Treatment of programmed death protein 1\/programmed death protein ligand 1 inhibitor-associated pneumonia based on the theory of strengthening fire and eating qi","volume":"09","author":"Yang","year":"2024","journal-title":"Glob. Chin. Med."},{"issue":"1071","key":"10.1016\/j.critrevonc.2024.104591_bib64","doi-asserted-by":"crossref","first-page":"20160723","DOI":"10.1259\/bjr.20160723","article-title":"Radio-pathological correlation of organizing pneumonia (OP): a pictorial review","volume":"90","author":"Zare Mehrjardi","year":"2017","journal-title":"Br. J. Radio."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104591_bib65","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1186\/s12890-022-02190-w","article-title":"Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease","volume":"22","author":"Zeng","year":"2022","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.critrevonc.2024.104591_bib66","first-page":"1407","article-title":"Current status of Chinese and Western medicine in immune checkpoint inhibitor-associated pneumonia","volume":"39","author":"Zeng","year":"2023","journal-title":"J. Chang. Univ. Tradit. Chin. Med."},{"key":"10.1016\/j.critrevonc.2024.104591_bib67","article-title":"Efficacy and safety of consolidation durvalumab after chemoradiation therapy for stage III non-small-cell lung cancer: a systematic review, meta-analysis, and meta-regression of real-world studies","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Pharm."},{"issue":"15","key":"10.1016\/j.critrevonc.2024.104591_bib68","doi-asserted-by":"crossref","first-page":"15998","DOI":"10.1002\/cam4.6244","article-title":"A nomogram model for predicting the risk of checkpoint inhibitor-related pneumonitis for patients with advanced non-small-cell lung cancer","volume":"12","author":"Zhang","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2024.104591_bib69","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/978-3-030-41008-7_13","article-title":"Immune-related adverse events: pneumonitis","volume":"1244","author":"Zhong","year":"2020","journal-title":"Adv. Exp. Med. Biol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824003342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824003342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T03:17:19Z","timestamp":1742181439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842824003342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":69,"alternative-id":["S1040842824003342"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104591","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in the study of immune checkpoint inhibitor-associated pneumonia","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104591","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104591"}}